|Publication number||US3632754 A|
|Publication date||Jan 4, 1972|
|Filing date||Feb 12, 1968|
|Priority date||Feb 12, 1968|
|Publication number||US 3632754 A, US 3632754A, US-A-3632754, US3632754 A, US3632754A|
|Inventors||Leslie L Balassa|
|Original Assignee||Lescarden Ltd|
|Export Citation||BiBTeX, EndNote, RefMan|
|Referenced by (76), Classifications (8), Legal Events (2)|
|External Links: USPTO, USPTO Assignment, Espacenet|
UnitedStates Patent 3,632,754 USE OF CHITIN FOR PROMOTING WOUND HEALING Leslie L. Balassa, Blooming Grove, N.Y., assignor t0 Lescarden Ltd., Goshen, N.Y.
N0 Drawing. Continuation-impart of application Ser. No. 619,007, Feb. 27, 1967. This application Feb. 12, 1968, Ser. No. 704,538
Int. Cl. A61k 17/00 US. Cl. 424-180 6 Claims ABSTRACT OF THE DISCLOSURE Wound healing compositions and the process of healing wounds with such compositions are described, the compositions containing chitin, partially depolymerized chitin or a chitin derivative.
This application is a continuation-in-part of my copending application Ser. No. 619,007 filed Feb. 27, 1967.
This invention relates to methods of promoting the healing of wounds and compositions therefor comprising chitin, and/ or chitin derivatives and/or partially depolymerized chitin.
Medicine has long been interested in improving the healing of wounds. Patients suffering from diabetes or undergoing extensive cortisone treatment show extremely slow rates of healing of any wounds which they receive. Thus, surgery on such patients involves additional risks not present with other patients. Moreover, rapid healing of wounds is particularly desired for patients in tropical countries where the risk of infection is high. Rapid healing is also desired in the case of soldiers who have been wounded in a battle zone and cannot easily and quickly be removed therefrom. Acceleration of wound healing is highly desirable in the case of patients who cannot readily be immobilized, such as farm animals.
In evaluating the utility of a material to promote wound healing, a reproducible test is necessary to give comparative data. Such a test method has been described by Prudden et al. in: The Acceleration of Wound Healing With Cartilage, Surgery, Gynecology and Obstetrics, 105 2283 (1957). In this method, rats are tested in pairs, each pair receiving an identical surgical incision, only the one rat of the pair receiving a measured dose of the material whose wound healing properties is to be determined. The pair is then kept in the same cage and the tensile strength of the wounds in the two rats is determined in millimeters of mercury. The difference in the tensile strengths between the treated rat and the control rat is expressed as the percentage improvement obtained. Considering biological variance it is believed that only differences of about 10% or more are significant.
There have been several recent developments reported concerning materials which promote wound healing. In this connection US. Pat. No. 3,232,836 describes the parenteral administration of N-acetylglucosamine as a wound healing material. Utilizing the test method of Prudden et al. referred to in the preceding paragraph, N-acetylglucosamine showed improvement in tensile strength of only about 10% whereas Prudden and his co-workers have reported significantly larger increases in wound healing by the use of cartilage preparations from various animals. Depending on the age and species of animal and the fineness of the cartilage powder, improvements ranging from to 40% in wound healing tensile strength have been reported by Prudden.
Now it has been discovered that finely divided chitin, partially depolymerized chitin, and chitin derivatives possess the ability to promote the healing of wounds.
3,632,754 Patented Jan. 4, 1972 ice Accordingly, one aspect of the present invention relates to novel methods of promoting and assisting the healing of wounds as, for example, damaged mammalian tissue, open ulcers, etc., and to compositions therefor.
Another aspect of the invention relates to significant improvements in wound healing strength achieved by the administration of finely divided chitin, partially depolymerized chitin or chitin derivatives to a patient.
An additional aspect of the present invention is concerned with articles of manufacture such as surgical bandages, surgical sutures, etc., containing the wound healing materials of the present invention.
These and other aspects of the present invention will be apparent from the following description.
Chitin is a polysaccharide, believed to be poly (N-acetylglucosamine) which forms the cell walls of fungi and the hard shell of insects and crustaceans. As used herein, the term chitin embraces naturally occurring chitin, synthetic chitin, as well as poly (N-acetylglucosamine) and its epimer poly (N-acetylgalactosamine). The partially depolymerized chitin, e.g. chitotriose, chitobiose, is a substance which retains its polymeric nature but has undergone a reduction in molecular weight (i.e. chain length) as a result of (1) enzymatic action such as by a chitinase enzyme, (2) chemical treatment such as acid hydrolysis or alkaline treatment, and (3) physical treatment.
The chitin derivatives contemplated are materials such as ethers formed with pharmaceutically-acceptable radi cals and esters or salts with pharmaceutically-acceptable acids. Examples of suitable derivatives include hydroxy lower alkyl chitin such as hydroxyethyl chitin, carboxy alkyl chitin such as carboxymethyl chitin, salts of carboxy lower alkyl chitin such as the zinc salt, lower alkyl chitin such as methyl chitin and ethyl chitin, chitin acetate, chitin nitrate, chitin citrate, chitin phosphate, N-acyl derivatives derived from monocarboxylic aliphatic acids such as N-formyl, N-acetyl, N-propionyl, N-caproyl, etc.
It is preferred to use natural chitin as the wound healing accelerator. The naturally occurring chitin is preferably chitin of fungal origin, both by reason of its ready availability and its high degree of effectiveness.
The degree of improvement in wound healing obtained with the chitin materials is at least equal to and in many instances greater than that derived from the cartilage materials of the prior art. The substantial improvement in rate of healing which is obtained from the use of poly (l I- acetylglucosamine), i.e., chitin, as compared to monomeric N-acetylglucosamine is particularly surprising. As compared to the great variability in cartilage depending on the animal, its age and the method of collecting the cartilage, chitin, particularly chitin of fungal origin, is a relatively uniform and easily obtained material.
The compositions of the present invention are applied using the same techniques and processes developed for cartilage, and N-acetylglucosamine. Thus, it is preferred to topically apply finely divided chitin directly to the wound surface. However, tablets, capsules or pellets of chitin may be prepared from mixtures of chitin, partially depolymerized chitin or chitin derivatives with wellknown pharmaceutical excipients such as starch, sugar, certain forms of clay, etc. Such tablets, capsules or pellets may be taken orally or implanted near the situs of the wound. Alternatively, a colloidal solution may be prepared from chitin, preferably in isotonic saline, or a watersoluble derivative of chitin may be dissolved preferably in isotonic saline solution, and the solution administered intramuscularly, parenterally or intravenously.
A powder or solution of chitin or of a chitin derivative may also be used to impregnate a surgical gauze or pad which is applied to the wound. Chitin may also be dissolved as the alkali chitin xanthate, spun into fibers and regenerated as the virtually undegraded polymer in accordance with the procedures described the prior art by Thor et a1. Partially deacetylated chitin filaments and fibers may be prepared in accordance with the procedure described in US. Pat. No. 2,040,880. These chitin fibers may then be used as surgical sutures or included in bandages or other support base for surgical dressings either in a woven or nonwoven fabric structure in the manner described in US. Pat. 3,196,075. Chitin or chitin derivative may also be made up into an ointment or salve. The use of nonactive carriers for the chitin is not preferred as the presence of extraneous matter in a wound frequently tends to interfere with the healing process due to the interposition effect.
As previously stated, where the chitin is to be applied by injection, i.e., either intramuscularly, parenterally or intravenously, it is first necessary to prepare a dispersion or a solution of the material in a pharmaceutically acceptable liquid. Colloidal solutions of chitin may be prepared using the method described by Lingappa and Lockwood in Nature, 189, page 158 (1961). When administered intravenously it is preferred to administer the compound in isotonic solution such as isotonic saline.
The chitin or chitin derivatives may be used alone, in admixture with each other, with cartilage, or may be coadministered with other therapeutically eifective agents such as ascorbic acid, ascorbyl palmitate, pharmaceutically acceptable zinc salts such as zinc oxide, zinc ascorbate, zinc sulfate and zinc stearate; antiseptics such as thimerosol and benzalkonium chloride; local anesthetics such as lidocaine and procaine; antibiotics such as chloramphenicol, sulfanilamide and ampicilline. Combinations of the therapeutically effective agents described above with chitin and/ or chitin derivatives may be used.
Suitable sources of chitin are from lobsters, shrimp and other crustacea. To utilize chitin from such sources, it is necessary to reduce the chitin in particle size to less than about 150 microns and preferably less than about 50 microns. Due to the tough and rather fibrous nature of chitin from such sources, this grinding is difficult and expensive. Accordingly, it is preferred to use chitin of fungal origin. The cell walls of fungi are made of chitin. It has been found that it is not necessary to extract the chitin from the remaining cell material. Thus, if desired, after suitable sterilization as by heat or gas (i.e., ethylene oxide), the entire fungal mat produced by fermentation of a fungus in a suitable nutrient medium may be ground and used to promote healing of wounds. Preferably, however, the fungal mat is treated to remove the extraneous materials leaving only the chitin skeletons. Purifying the material in this manner eliminates the nonchitinous materials, thus substantially reducing the possibility of an allergic reaction and eliminating any interference with the healing process which might be cause by such materials.
Finely divided chitin or chitin derivatives may be ap plied topically by blowing a metered amount of the material onto the wound using a hand atomizer. Alternatively, it may be applied by dusting as from a hand shaker or may be placed together with an inert gas under increased pressure (i.e., above atmospheric pressure) in a pressure vessel. In this latter means of application, termed aerosol application, the finely divided chitin or chitin derivative, optionally with other medicaments as indicated, may be packaged as a dry aerosol powder as de scribed in Dutch patent application 6,415,252, published July 5, 1965 (this patent application is directed to a medicament for bovine mastitis but the method of aerosol packaging described is applicable to powdered medicament having the described particle size) or as an aerosol foam.
In the following examples, the wound healing efliciency of the various chitinous materials is determined by using the method of Prudden et a1. as described above.
4 In general, at least 10 pairs of rats are used to obtain a meaningful average for each material tested. In each of these examples a powder insufliator is used to apply 2 to 10 mg./cm. of wound surface of the material tested.
EXAMPLE 1 Commercial lobster shell chitin is ground to a fine powder in a laboratory four-quart size porcelain jar mill loaded with one-inch size (average) flint pebbles in a weight ratio of 1 chitin to 2 pebbles. Dry Ice is then put on top of the mill charge and the mill is kept open for 5 minutes to allow the CO to displace the air in the mill. The lid of the mill is then clamped on tight and the grinding carried out for 96 hours. Approximately 50% of the powdered chitin passed through a 40 micron screen.
The whole powdered chitin so produced is then applied to the 45 test rats of 45 pairs of rats used in the Prudden et al. assay method described above. The percent of wound healing for the treated rats, stating the control rats as 100%, is 122%, i.e., the use of chitin results in an average 22% increase in wound healing activity.
EXAMPLES 2-5 Various fungi are grown on either brain-heart infusion (200 gm. calf brain, 250 gm. beef heart, 10 gm. proteose peptone, 2 gm. dextrose, 5 gm. sodium chloride and 2.5 gm. disodium phosphate) called BHI or on Sabourauds broth (40 gm. dextrose and 10 gm. bacto-peptone) called SAB. The cultures are grown in shallow layers of media contained in flasks and held stationary until good growth and extensive sporulation occurs. Prior to collection of the growth mats, the cultures are killed by placing the flasks into a closed oven under CO at 127 C. for three hours. The flasks are then cooled in the oven for an additional one hour and fifteen minutes. Culture broths are removed by filtration through Buchner funnels and the growth mats washed with distilled water. The mats are then frozen and lyophilized and the dry products ground in a mortar with a pestle under CO No attempt is made to purify the chiten. Twelve pairs of rats are used for each test. Some inflammation is observed on all treated wounds and infection on several. The increases in wound healing obtained may be all the more significant in view of those adverse factors.
100 grams of dried fungus material (obtained from Penicillium fungus of Example 4, cultured on a BHI medium, sterilized by boiling the fungus with the medium and then filtering, washing with distilled water and drying the fungus material) is defatted by extracting the solventsoluble fatty materials with 1000 ml. chloroform at room temperature. The chloroform is removed by filtering and then drying at reduced pressure in a vacuum desiccator.
The defatted fungus material is treated with 2000 ml. 1.0 N-NaOH solution for 18 hours at room temperature. The material is then acidified with HCl. Thereafter the material is dialyzed in distilled water unitl the wash water is free from chlorine ions. This procedure is repeated until a substantially purified material is obtained. The material is dried in a vacuum below 50 C. and is a gray, friable mass.
The dried material is ground in a laboratory mortar and screened through a 400 mesh standard screen. When the screened material is applied to 20 test rats of 20 pairs of rats there is obtained an average of about 25% increase in the wound healing of the treated rats over the untreated control rats.
EXAMPLE 7 Lobster shell chitin is purified by first sl-urrying it in 10% aqueous NaOH for minutes at 80 C., then it is washed, drained and slurried in HCl for 5 minutes at 80 C., drained, slurried in water, the pH of the water adjusted to 6 with dilute aqueous NaOH, and finally drained and dried.
The dried chitin material is pulverized to a fineness of about 40 microns. The material shows an average 25% increase in the wound healing over the untreated control rats.
Although the present invention has been described in conjunction with preferred embodiments, it is to be understood that modifications and variations may be resorted to without departing from the spirit and scope thereof, as those skilled in the art will readily understand.
What is claimed is:
1. A process for facilitating healing of a wound in a mammal which comprises administering to said mammal a therapeutically effective amount of chitin.
2. A process according to claim 1, wherein said chitin is of fungal origin.
3. A process according to claim 1 wherein said chitin is of crustacea origin.
4. A process according to claim 2 wherein said material of fungal origin is a sterilized, defatted material selected 6 from the class consisting of Mucor spinosus, Aspergillus niger, Penicillium and Cryptococcus.
5. A process according to claim 2, wherein the chitin consists of the purified cell walls of fungi.
6. A process for facilitating healing of a wound in a mammal which comprises topically applying to said Wound in said mammal a therapeutically effective amount of chitin.
References Cited UNITED STATES PATENTS ALBERT T. MEYERS, Primary Examiner D. M. STEPHENS, Assistant Examiner US. Cl. X.R. 424
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3911098 *||Feb 11, 1974||Oct 7, 1975||American Cyanamid Co||Medicament carrier|
|US3982537 *||Dec 30, 1974||Sep 28, 1976||Louis Bucalo||Dynamic implants and method for implanting the same|
|US3988411 *||Mar 14, 1975||Oct 26, 1976||American Cyanamid Company||Spinning and shaping poly-(N-acetyl-D-glucosamine)|
|US3989535 *||Mar 14, 1975||Nov 2, 1976||American Cyanamid Company||Solution of poly(N-acetyl-D-glucosamine)|
|US4074366 *||Jul 22, 1976||Feb 21, 1978||American Cyanamid Company||Poly(N-acetyl-D-glucosamine) products|
|US4074713 *||Jul 22, 1976||Feb 21, 1978||American Cyanamid Company||Poly(N-acetyl-D-glucosamine) products|
|US4086335 *||Oct 29, 1975||Apr 25, 1978||Bruscato Frank N||Pharmaceutical tablets containing chitin as a disintegrant|
|US4120527 *||Apr 15, 1977||Oct 17, 1978||Caterpillar Tractor Co.||Cab design|
|US4486416 *||Mar 2, 1981||Dec 4, 1984||Soll David B||Protection of human and animal cells subject to exposure to trauma|
|US4532134 *||Nov 8, 1982||Jul 30, 1985||Malette William Graham||Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound|
|US4532267 *||Feb 15, 1984||Jul 30, 1985||Board Of Regents, University Of Washington||Vision correction lens made from an aminopolysaccharide compound or an ether or ester thereof|
|US4572906 *||Oct 2, 1984||Feb 25, 1986||Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government||Chitosan based wound dressing materials|
|US4623539 *||Mar 25, 1985||Nov 18, 1986||Tunc Deger C||Nutrient barrier polysaccharide compositions and method of use|
|US4920158 *||Aug 22, 1988||Apr 24, 1990||Medipro Sciences Limited||Hydrogel-forming wound dressing or skin coating material|
|US4938950 *||Dec 22, 1987||Jul 3, 1990||Wella Aktiengesellschaft||Cosmetic composition based upon chitosan and ampholytic copolymerizates, as well as new chitosan/polyampholyte salts|
|US4994277 *||Oct 31, 1989||Feb 19, 1991||Pfizer Hospital Products Group, Inc.||Use of xanthan gum for preventing adhesions|
|US5013769 *||Feb 6, 1990||May 7, 1991||Medipro Sciences Limited||Method of making a hydrogel-forming wound dressing or skin coating material|
|US5093319 *||Jan 24, 1991||Mar 3, 1992||Pfizer Hospital Products Group, Inc.||Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions|
|US5141925 *||Apr 23, 1990||Aug 25, 1992||Trustees Of Tufts College||Vivo methods for treating coccidiosis|
|US5300494 *||Jul 12, 1989||Apr 5, 1994||Union Carbide Chemicals & Plastics Technology Corporation||Delivery systems for quaternary and related compounds|
|US5605938 *||May 31, 1991||Feb 25, 1997||Gliatech, Inc.||Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate|
|US5705177 *||May 29, 1992||Jan 6, 1998||Gliatech Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US5705178 *||Dec 8, 1993||Jan 6, 1998||Gliatech, Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US5733884 *||Nov 7, 1995||Mar 31, 1998||Nestec Ltd.||Enteral formulation designed for optimized wound healing|
|US5994325 *||Jun 6, 1995||Nov 30, 1999||Gliatech Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US6020326 *||Jun 6, 1995||Feb 1, 2000||Gliatech Inc.||Method for inhibition of bone growth by anionic polymers|
|US6083930 *||Jun 6, 1995||Jul 4, 2000||Gliatech Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US6117851 *||Dec 12, 1997||Sep 12, 2000||Lescarden Inc.||Treatment of osteoarthritis by administering poly-N-acetyl-D-glucosamine|
|US6127348 *||Sep 1, 1999||Oct 3, 2000||Gliatech, Inc.||Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers|
|US6150581 *||Jun 7, 1995||Nov 21, 2000||United States Surgical Corporation||Chitosan/alginate anti-adhesion barrier|
|US6693188||Aug 8, 2001||Feb 17, 2004||Cargill Incorporated||N-acetyl-D-glucosamine and process for producing N-acetyl-D-glucosamine|
|US7371403 *||Dec 23, 2003||May 13, 2008||Providence Health System-Oregon||Wound dressing and method for controlling severe, life-threatening bleeding|
|US7413881||Jun 15, 2005||Aug 19, 2008||Cargill, Incorporated||Chitosan and method of preparing chitosan|
|US7482503||Jun 14, 2002||Jan 27, 2009||Providence Health System-Oregon||Wound dressing and method for controlling severe, life-threatening bleeding|
|US7488812||Apr 2, 2003||Feb 10, 2009||Cargill, Incorporated||Chitosan production|
|US7816514||Oct 13, 2003||Oct 19, 2010||Cargill, Incorporated||Glucosamine and method of making glucosamine from microbial biomass|
|US7923437||Mar 31, 2006||Apr 12, 2011||Cargill, Incorporated||Water soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same|
|US8034925||Mar 18, 2010||Oct 11, 2011||Cargill, Incorporated||Glucosamine and method of making glucosamine from microbial biomass|
|US8062669||Dec 16, 2004||Nov 22, 2011||Bioalliance Pharma||Vectorization system comprising nanoparticles of homogenous size of at least one polymer and at least one positively charged polysaccharide and method for the preparation thereof|
|US8222232||Mar 31, 2006||Jul 17, 2012||Cargill, Incorporated||Glucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass|
|US8269058||Jul 16, 2008||Sep 18, 2012||Hemcon Medical Technologies, Inc.||Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan|
|US8313474||Dec 17, 2007||Nov 20, 2012||Hemcon Medical Technologies, Inc.||Method for preparing a compressed wound dressing|
|US8481512||Jun 16, 2010||Jul 9, 2013||Marine Polymer Technologies, Inc.||Compositions and methods for modulation of vascular structure and/or function|
|US8517979||Dec 21, 2009||Aug 27, 2013||Abbott Laboratories||Carriers for hemostatic tract treatment|
|US8668924||Oct 18, 2010||Mar 11, 2014||Providence Health System—Oregon||Wound dressing and method for controlling severe, life-threatening bleeding|
|US8715719||Jun 16, 2010||May 6, 2014||Abbott Vascular, Inc.||Stable chitosan hemostatic implant and methods of manufacture|
|US8741335||Jul 13, 2006||Jun 3, 2014||Hemcon Medical Technologies, Inc.||Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan|
|US8859528||Jul 1, 2013||Oct 14, 2014||Marine Polymer Technologies, Inc.||Compositions and methods for modulation of vascular structure and/or function|
|US8920514||Dec 20, 2007||Dec 30, 2014||Providence Health System—Oregon||Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ|
|US8951565||Apr 17, 2014||Feb 10, 2015||Hemcon Medical Technologies, Inc.||Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as chitosan|
|US8992453||Mar 8, 2012||Mar 31, 2015||Marine Polymer Technologies, Inc.||Vascular access preservation in hemodialysis patients|
|US9004918||Jul 12, 2010||Apr 14, 2015||Hemcon Medical Technologies, Inc.||Compositions, assemblies, and methods applied during or after a dental procedure to ameliorate fluid loss and/or promote healing, using a hydrophilic polymer sponge structure such as chitosan|
|US9132206||Jan 5, 2015||Sep 15, 2015||Hemcon Medical Technologies, Inc.||Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as chitosan|
|US20040077055 *||Oct 13, 2003||Apr 22, 2004||Cargill, Incorporated||Glucosamine and method of making glucosamine from microbial biomass|
|US20040243043 *||Dec 23, 2003||Dec 2, 2004||Mccarthy Simon J,||Wound dressing and method for controlling severe, life-threatening bleeding|
|US20050038369 *||Jun 14, 2002||Feb 17, 2005||Gregory Kenton W.||Wound dressing and method for controlling severe, life-threatening bleeding|
|US20050215774 *||Apr 2, 2003||Sep 29, 2005||Trinkle Jamea R||Chitosan production|
|US20050245482 *||Jun 15, 2005||Nov 3, 2005||Weiyu Fan||Chitosan and method of preparing chitosan|
|US20060003965 *||Oct 31, 2003||Jan 5, 2006||Fosdick Lawrence D||N-acetyl-d-glucosamine (nag) supplemented food products and beverages|
|US20060004314 *||Aug 12, 2005||Jan 5, 2006||Hemcon, Inc.||Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chistosan|
|US20060058263 *||Oct 31, 2003||Mar 16, 2006||Rogers Brent D||Heat pasturized liquids containing glucosamine|
|US20060134220 *||Dec 16, 2004||Jun 22, 2006||Bioalliance Pharma||Vectorization system comprising nanoparticles of homogenous size of at least one polymer and at least one positively charged polysaccharide and method for the preparation thereof|
|US20060172392 *||Mar 31, 2006||Aug 3, 2006||Cargill, Incorporated||Water soluble beta-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same|
|US20060178344 *||Mar 31, 2006||Aug 10, 2006||Cargill, Incorporated||Glucosamine and N-acetylglucosamine and methods of making the same fungal biomass|
|US20060211973 *||Mar 17, 2005||Sep 21, 2006||Gregory Kenton W||Systems and methods for hemorrhage control and or tissue repair|
|US20060246114 *||Oct 31, 2003||Nov 2, 2006||Rogers Brent D||Multiple component food product useful for delivering glucosamine and/or nacetyl-d-glucosamine|
|DE3342886A1 *||Nov 26, 1983||Jun 5, 1985||Univ Delaware||Wound healing agent, its composition and use|
|DE3437184A1 *||Oct 10, 1984||Apr 17, 1986||Eduard Iwan||Composition for the treatment of skin burns and a process for the preparation of this composition|
|EP0002506A1 *||Dec 8, 1978||Jun 27, 1979||Wella Aktiengesellschaft||Use of compositions for conditioning as well as washing hair|
|EP0412744A1 *||Aug 6, 1990||Feb 13, 1991||Unilever Plc||Hair treatment composition|
|EP0412745A1 *||Aug 6, 1990||Feb 13, 1991||Unilever Plc||Hair setting composition|
|EP0957925A1 *||Dec 12, 1997||Nov 24, 1999||Lescarden, Inc.||Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine|
|WO1985003716A1 *||Jan 31, 1985||Aug 29, 1985||Washington Res Found||Vision correction lens made from an aminopolysaccharide compound or an ether or ester thereof|
|WO1986005789A1 *||Mar 25, 1986||Oct 9, 1986||Biocarb Ab||Carbohydrate derivatives and compositions thereof for therapeutic or diagnostic use, and methods for their use|
|WO2011026869A2||Sep 1, 2010||Mar 10, 2011||Medovent Gmbh||Tissue dressing kit|
|WO2013109004A1||Dec 28, 2012||Jul 25, 2013||Cg Bio Co., Ltd.||Antimicrobial wound-covering material and method for manufacturing same|
|U.S. Classification||514/55, 424/538|
|International Classification||A61L15/28, C08B37/08|
|Cooperative Classification||C08B37/003, A61L15/28|
|European Classification||A61L15/28, C08B37/00M3B2|
|Apr 1, 1983||AS01||Change of name|
Owner name: LESCARDEN INC.,
Effective date: 19830105
Owner name: LESCARDEN LTD.
|Apr 1, 1983||AS||Assignment|
Owner name: LESCARDEN INC.,
Free format text: CHANGE OF NAME;ASSIGNOR:LESCARDEN LTD.;REEL/FRAME:004123/0510
Effective date: 19830105